Pechan P A, Fotaki M, Thompson R L, Dunn R, Chase M, Chiocca E A, Breakefield X O
Department of Neurology, Massachusetts General Hospital East, Boston, USA.
Hum Gene Ther. 1996 Oct 20;7(16):2003-13. doi: 10.1089/hum.1996.7.16-2003.
Recombinant and amplicon vectors derived from herpes simplex virus type 1 (HSV-1) have proven to be an efficient means of gene delivery to cells in culture and in vivo. In this study, a system was developed to make propagation of the amplicon vector and helper virus mutually dependent on each other, in a "piggyback' fashion. This combined system supports maintenance and enrichment of the amplicon vector when propagating stocks, while allowing the helper virus to serve as a recombinant vector in its own right. Amplicons bearing a gene essential for HSV-1 replication, IE3, as well as the Escherichia coli lacZ marker gene, were propagated using a mutant virus (d120) deleted in the same essential gene. Vector stocks could be propagated in Vero cells and other cultured cells not transfected with the IE3 gene with markedly delayed cytopathic effects, as compared to wild-type virus. Relatively high titers of amplicon vectors (6 x 10(7) infectious units/ml) were achieved with this piggyback system in Vero cells, with an apparent ratio of amplicon vector: helper virus of up of 5:1 under some conditions; however, recombinant wild-type virus was also generated. Injection of these stocks into experimental gliomas in rodent brain revealed gene delivery to tumor cells mediated by both amplicon vectors (lacZ) and helper virus (HSV-thymidine kinase), with no apparent neuropathology of normal brain. This basic piggyback vector model is amenable to modifications to promote conditional propagation of vectors in vivo and to allow incorporation of multiple transgene elements into both the amplicon and recombinant helper virus vectors.
源自单纯疱疹病毒1型(HSV-1)的重组载体和扩增子载体已被证明是在体外培养和体内将基因导入细胞的有效手段。在本研究中,开发了一种系统,使扩增子载体和辅助病毒以“搭载”方式相互依赖进行增殖。这种组合系统在扩增病毒储备时支持扩增子载体的维持和富集,同时允许辅助病毒本身作为重组载体。携带HSV-1复制必需基因IE3以及大肠杆菌lacZ标记基因的扩增子,使用在相同必需基因上缺失的突变病毒(d120)进行增殖。与野生型病毒相比,载体储备可在未转染IE3基因的Vero细胞和其他培养细胞中增殖,细胞病变效应明显延迟。利用这种搭载系统在Vero细胞中获得了相对较高滴度的扩增子载体(6×10⁷感染单位/毫升),在某些条件下扩增子载体与辅助病毒的明显比例高达5∶1;然而,也产生了重组野生型病毒。将这些病毒储备注射到啮齿动物脑内的实验性胶质瘤中,结果显示扩增子载体(lacZ)和辅助病毒(HSV-胸苷激酶)均可介导基因传递至肿瘤细胞,且对正常脑无明显神经病理学影响。这种基本的搭载载体模型易于修改,以促进载体在体内的条件性增殖,并允许将多个转基因元件整合到扩增子和重组辅助病毒载体中。